

DAFTAR PUSTAKA

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl.* 2013;3(1):5–6.
2. Moe SM. Disorders of Phosphorous Homeostasis in CKD. In: Hsu CH, editor. *Calcium and Phosphate Metabolism Management in Chronic Renal Disease.* Springer US; 2006. p. 13–28.
3. Wesseling-Perry K, Jüppner H. The osteocyte in CKD: New concepts regarding the role of FGF23 in mineral metabolism and systemic complications. *Bone.* 2013;54(2):222–9.
4. Fourtounas C. Phosphorus metabolism in chronic kidney disease. *Hippokratia.* 2011;15(SUPPL. 1):50–2.
5. Russo D, Battaglia Y. Clinical Significance of FGF-23 in Patients with CKD. *Int J Nephrol.* 2011;2011:1–5.
6. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. *J Am Soc Nephrol.* 2005;16(7):2205–15.
7. Marsell R, Grundberg E, Krajsnik T, et al. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. *Eur J Endocrinol.* 2008;158(1):125–9.
8. Fliser D, Kollerits B, Neyer U, et al. Fibroblast Growth Factor 23 (FGF23)

- predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study. *J Am Soc Nephrol.* 2007;18(9):2601–8.
9. Hu X, Ma X, Luo Y, et al. Associations of serum fibroblast growth factor 23 levels with obesity and visceral fat accumulation. *Clin Nutr.* 2018;37(1):223–8.
 10. Masson S, Latini R, Mureddu GF, et al. The Fibroblast Growth Factor-23/Vitamin D Axis, Left Ventricular Mass And Mortality In Elderly People. *Eur Heart J.* 2013;34(Suppl1):123.
 11. Fyfe-Johnson AL, Alonso A, Selvin E, et al. Serum fibroblast growth factor-23 and incident hypertension: The Atherosclerosis Risk in Communities (ARIC) Study. *J Hypertens.* 2016;34(7):1266–72.
 12. Titan SM, Zatz R, Gracioli FG, et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. *Clin J Am Soc Nephrol.* 2011;6(2):241–7.
 13. Rocco M V., Berns JS. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am J Kidney Dis.* 2012;60(5):850–86.
 14. Crews DC, Bello AK, Saadi G. Burden, Access, and Disparities in Kidney Disease. *Kidney Dis.* 2019;5(2):126–33.
 15. Suwitra K. Penyakit Ginjal Kronik. In: Setiati S, Alwi I, Sudoyo AW, K. MSi, Setiyohadi B, Syam AF, editors. *Buku Ajar Ilmu Penyakit Dalam.* VI. Jakarta: Interna Publishing; 2015. p. 2163.
 16. Indonesian Renal Registry. 10th Report Of Indonesian Renal Registry. 2017;1–40.

17. Nitta K, Nagano N, Tsuchiya K. Fibroblast growth factor 23/klotho axis in chronic kidney disease. *Nephron - Clin Pract.* 2014;128(1–2):1–10.
18. Richter B, Haller J, Haffner D, et al. Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. *Eur J Physiol.* 2016;468(9):1621–35.
19. Hanudel MR, Laster M, Salusky IB. Non-renal-Related Mechanisms of FGF23 Pathophysiology. *Curr Osteoporos Rep.* 2018;16(6):724–9.
20. Lanske B, Razzaque MS. Mineral metabolism and aging: the FGF-23 enigma Beate. *Curr Opin Nephrol Hypertens.* 2006;16(4):311–8.
21. Hanks LJ, Casazza K, Judd SE, et al. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. *PLoS One.* 2015;10(3):1–12.
22. Yan J, Zhang M, Ni Z, et al. Associations of serum fibroblast growth factor 23 with dyslipidemia and carotid atherosclerosis in chronic kidney disease stages 3-5D. *Int J Clin Exp Med.* 2017;10(9):13588–97.
23. Smith ER. The use of fibroblast growth factor 23 testing in patients with kidney disease. *Clin J Am Soc Nephrol.* 2014;9(7):1283–303.
24. Vázquez-Sánchez S, Poveda J, Navarro-García JA, et al. An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. *Front Physiol.* 2021;12(March):1–19.
25. Pavik I, Jaeger P, Ebner L, et al. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: A sequence suggested from a cross-sectional

- study. *Nephrol Dial Transplant*. 2013;28(2):352–9.
26. Tanaka S, Fujita SI, Kizawa S, et al. Association between FGF23, α -Klotho, and cardiac abnormalities among patients with various chronic kidney disease stages. *PLoS One*. 2016;11(7):1–17.
 27. Vervloet MG. FGF23 measurement in chronic kidney disease: What is it really reflecting? *Clin Chim Acta*. 2020;505(March):160–6.
 28. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. *Kidney Int*. 2011;79(12):1370–8.
 29. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. *Kidney Int* [Internet]. 2009;76(SUPPL. 114):S34–42. Available from: <http://dx.doi.org/10.1038/ki.2009.405>
 30. Souma N, Isakova T, Lipiszko D, et al. Fibroblast growth factor 23 and cause-specific mortality in the general population: The northern Manhattan study. *J Clin Endocrinol Metab*. 2016;101(10):3779–86.
 31. Speer T, Groesdonk H V., Zapf B, et al. A single preoperative FGF23 measurement is a strong predictor of outcome in patients undergoing elective cardiac surgery: A prospective observational study. *Crit Care*. 2015;19(1):1–10.
 32. Gutiérrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. *Clin J Am Soc Nephrol*. 2011;6(12):2871–8.

33. Wahl P, Xie H, Scialla J, et al. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. *Clin Sci*. 2021;135:16691–87.
34. Akhabue E, Montag S, Reis J, et al. Fibroblast Growth Factor-23 and Incident Hypertension in Young and Middle-Aged Adults. *Hypertension*. 2018;72(1):70–6.
35. Freundlich M, Gamba G, Rodriguez-Iturbe B. Fibroblast growth factor 23—Klotho and hypertension: experimental and clinical mechanisms. *Pediatr Nephrol*. 2021;36(10):3007–22.

Lampiran



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN



RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 219/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 5 April 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21030192		No Sponsor	
Peneliti Utama	dr. Akiko Syawalidhany Tahir		Protokol	
Judul Peneliti	Hubungan Laju Filtrasi Glomerulus dengan Kadar Fibroblast Growth Factor-23 pada Penyakit Ginjal Kronik			
No Versi Protokol	1	Tanggal Versi	30 Maret 2021	
No Versi PSP		Tanggal Versi		
Tempat Penelitian	Rumah Sakit Dr Wahidin Sudirohusodo Makassar dan Jejarungnya			
Jenis Review	<input checked="" type="checkbox"/> Exempted	Masa Berlaku	Frekuensi review lanjutan	
	<input type="checkbox"/> Expedited	5 April 2021		
	<input type="checkbox"/> Fullboard Tanggal	sampai		
		5 April 2022		
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama	Tanda tangan		
	Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)			
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama	Tanda tangan		
	dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)			

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapo SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan